The Subcutaneous Biologic Drugs and Affiliated Technologies Market is Estimated to be Worth Over USD 180 Billion by 2030, Claims Roots Analysis - Seite 2

By 2030, revenues from sales of self-medication enabling devices are estimated to reach USD 10 billion
Currently, prefilled syringes are estimated to be responsible for the dominant share (over 40%) of revenues generated in this market. However, in the foreseen future, the contributions of other drug delivery devices, such as large volume wearable injectors (for non-insulin biologics) and autoinjectors, are expected to grow at a relatively faster pace (CAGR ~40% and ~10%, respectively).

Moreover, ~80% of revenues of subcutaneous technology developers are estimated to be generated through milestone payments
As the demand for subcutaneous drug formulations continues to increase, more licensing agreements between drug and technology developers are likely to be inked. From the technology licensing perspective, the opportunity is anticipated to grow at a CAGR of over 15% during the forecast period (2020-2030).

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

• Who are the leading drug developers engaged in the development of subcutaneous biologics?
• Who are the leading subcutaneous drug delivery device developers?
• How many subcutaneous biologics are presently marketed / under clinical evaluation?
• What are the popular technologies / platforms being used for the development and formulation of subcutaneous biologics?
• What kind of partnership models are commonly adopted by stakeholders in this industry?
• What are the factors that are likely to influence the evolution of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:

• Phase of development
• Approved
• Pre-registration & Phase III
• Phase II & Phase II/III

• Type of molecule
• Cell and gene therapies
• Monoclonal antibodies
• Proteins
• Peptides (recombinant)
• Vaccines
• Others

• Target therapeutic area
• Autoimmune disorders
• Blood disorders
• Bone disorders
• Genetic disorders
• Metabolic disorders
• Neurological disorders
• Oncological disorders
• Respiratory disorders
• Others

• Type of drug delivery system
• Large volume wearable injectors
• Autoinjectors
• Prefilled syringes
• Needle-free injectors
• Drug reconstitution systems

• Revenues from licensing deals
• Upfront payments
• Milestone payments

• Key geographical regions
• North America
• Europe
• Asia Pacific
• Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, a significant increase in demand for subcutaneous biologics and affiliated drug delivery systems is likely to be observed in the foreseen future. The report includes detailed transcripts of discussions held with the following experts: